Identification of BXDC2 as a Key Downstream Effector of the Androgen Receptor in Modulating Cisplatin Sensitivity in Bladder Cancer

SIMPLE SUMMARY: It remains unclear why chemotherapy is often ineffective in patients with bladder cancer. Meanwhile, we previously reported that male sex hormones (i.e., androgens) could considerably reduce the efficacy of cisplatin, an anti-cancer drug used as the first-line treatment against advan...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancers (Basel)
Autores principales: Jiang, Guiyang, Teramoto, Yuki, Goto, Takuro, Mizushima, Taichi, Inoue, Satoshi, Ide, Hiroki, Nagata, Yujiro, Kashiwagi, Eiji, Baras, Alexander S., Netto, George J., Yang, Zhiming, Miyamoto, Hiroshi
Formato: Artigo
Lenguaje:Inglês
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7956795/
https://ncbi.nlm.nih.gov/pubmed/33652650
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13050975
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares